Clinical Orthopaedics and Related Research®

, Volume 468, Issue 8, pp 2152–2159

The Efficacy of Periarticular Multimodal Drug Infiltration in Total Hip Arthroplasty

  • Constant A. Busch
  • Michael R. Whitehouse
  • Benjamin J. Shore
  • Steven J. MacDonald
  • Richard W. McCalden
  • Robert B. Bourne
Clinical Research Hip

DOI: 10.1007/s11999-009-1198-7

Cite this article as:
Busch, C.A., Whitehouse, M.R., Shore, B.J. et al. Clin Orthop Relat Res (2010) 468: 2152. doi:10.1007/s11999-009-1198-7

Abstract

Background

Patient-controlled analgesia is a widely used and effective method of controlling pain after THA. This method is associated with substantial undesirable side effects. Local infiltration has been introduced in an attempt to reduce opioid requirements postoperatively, but its ability to reduce pain without complications is still questioned.

Questions/Purposes

We evaluated patient-controlled analgesia use, pain and satisfaction scores, complication rates, and ropivacaine levels associated with the use of periarticular multimodal drug infiltration in THA.

Patients and Methods

We randomized 64 patients undergoing THA to receive a periarticular intraoperative multimodal drug injection or to receive no injection. All patients received patient-controlled analgesia for 24 hours after surgery. The final assessment was at 6 weeks.

Results

Patients receiving the periarticular injection used less patient-controlled analgesia 6 hours postoperatively. The 24-hour patient-controlled analgesia requirement postsurgery also was less. The visual analog scale score for pain on activity in the postanesthetic care unit was less for patients who received an injection. The visual analog scale satisfaction score was similar in the two groups throughout the followup period. Recorded unbound ropivacaine levels were 2.5 times lower than toxic levels.

Conclusions

Periarticular intraoperative injection with multimodal drugs can reduce postoperative patient-controlled analgesia requirements and pain on activity in patients undergoing THA with no apparent increase in risk.

Level of Evidence

Level I, therapeutic study. See the guidelines online for a complete description of level of evidence.

Copyright information

© The Association of Bone and Joint Surgeons® 2009

Authors and Affiliations

  • Constant A. Busch
    • 1
  • Michael R. Whitehouse
    • 2
  • Benjamin J. Shore
    • 3
  • Steven J. MacDonald
    • 3
  • Richard W. McCalden
    • 3
  • Robert B. Bourne
    • 3
  1. 1.Ashford and St Peter’s Hospital NHS TrustChertseyEngland
  2. 2.Bristol Implant Research Centre, Avon Orthopaedic CentreSouthmead HospitalBristolEngland
  3. 3.London Health Sciences Centre–University CampusLondonCanada

Personalised recommendations